Aurige Pharma LLC

Form 483 issued August 26, 2022 · Durham, North Carolina

Inspection
Aug 22 – Aug 26, 2022
Observations
1
Pages
3
FEI number
3014028588

In short: On August 26, 2022, FDA issued a Form 483 with 1 observation to Aurige Pharma LLC in Durham, North Carolina (FEI 3014028588) after an inspection that ran Aug 22 – Aug 26, 2022. The investigators were Shelby N. Turner and Tyler R. Courtney. Most observations concern cAPA; the most-cited regulation is 21 CFR 820.100 (corrective and preventive action).

At a glance

1 of 1 observations on this 483 concern capa.

CAPA1

Most cited: 21 CFR 820.100 (1×)

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    Procedures for corrective and preventive action have…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Aurige Pharma LLC?

FDA listed 1 observation on this Form 483, mostly about cAPA. The most-cited regulation is 21 CFR 820.100 (corrective and preventive action). The opening words of each observation are shown on this page.

Who inspected Aurige Pharma LLC?

Shelby N. Turner and Tyler R. Courtney are named on this Form 483, for the inspection of Aug 22 – Aug 26, 2022. Each investigator has a profile showing what they cite most.

When was Aurige Pharma LLC inspected by FDA?

The inspection ran Aug 22 – Aug 26, 2022, and the Form 483 is dated August 26, 2022.

How do I get the full Form 483 for Aurige Pharma LLC?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free